China’s Beijing SL Pharmaceutical Co., Ltd (SHE: 002038) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its Category 1 chemical drug, MBT-1608. The drug is targeted for the treatment of hepatitis C virus (HCV) and will be co-developed with Beijing Meibeita Pharmaceutical Research Co., Ltd.
MBT-1608: Development and Potential
MBT-1608 is a molecule reconstructed based on sofosbuvir and has shown promising effects in animal experiments, including antioxidant, anti-liver injury, lipid-lowering, neuroprotective, and membrane protective properties. These findings suggest a broad therapeutic potential for MBT-1608 in treating HCV and possibly other related conditions.
Clinical Development Plans
The NMPA’s approval marks a significant step forward in the clinical development of MBT-1608. The upcoming Phase I clinical study will be crucial in evaluating the safety and efficacy of the drug in human subjects, paving the way for further development and potential market approval.-Fineline Info & Tech
